



**Coalition for Clinical and Translational Science
Legislative Agenda
119th Congress, 2nd Session**

About the Coalition

The Association for Clinical and Translational Science, the Clinical Research Forum, the CTSA PIs, and the related stakeholder community work together through the Coalition for Clinical and Translational Science (CCTS) to speak out with a unified voice on behalf of the clinical and translational research community. CCTS is a nationwide, grassroots network of dedicated individuals who seek to educate Congress and the administration about the value and importance of clinical and translational research, and research training and career development activities. Our goals are to ensure that the full spectrum of medical research is adequately funded, the next generation of researchers is well-prepared, and the regulatory and public policy environment facilitates ongoing expansion and advancement of the field of clinical and translational science.

About the Full Spectrum of Medical Research

CCTS supports the full spectrum of medical research to ensure that breakthroughs in basic science are translated into the innovative therapies and diagnostic tools that improve health and healthcare. The field of clinical and translational science is focused on improving outcomes by modernizing many of the steps from basic science research to clinical trials. Beyond research activities and programs, bolstering training and career development opportunities for young investigators is of critical importance to adequately prepare the next generation of medical researchers and ensure that scientific advancement can continue.

Fiscal Year 2027 Appropriations Recommendations

- Please provide the National Institutes of Health (NIH) with at least \$51.3 billion, an 8.5% increase over 2026.
- Please provide the [National Center for Advancing Translational Science](#) (NCATS) at NIH with a proportional funding increase for FY 2027, including:
 - At least \$660 million in dedicated line-item funding for the flagship [Clinical and Translational Science Awards](#) (CTSA) program, including \$30 million for High Impact Research and Research Infrastructure Programs (RC2) awards and CTSA Consortium Innovation Awards (CCIAs) that leverage the national CTSA Consortium in its breaking down barriers to the translation of research into impact on our nation's health. The CTSA program is central to ongoing efforts to modernize and enhance the full spectrum of medical research at NIH, and annual committee instructions and funding serve an important function of preserving the size, scope, and strategic direction of CTSAs.

- Please provide the [National Institute of General Medical Sciences](#) (NIGMS) at NIH with a proportional funding increase for FY 2027, including at least a \$20 million increase for the Institutional Development Award (IDeA) program.
- Please encourage partnership opportunities between the Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTRs) and CTSAAs that preserve the autonomy of both programs while removing barriers to allow them to effectively partner for rapid scientific advancement and improved local care and research. The IDeA-CTR program (under NIGMS) broadens the scope of medical research by giving a boost to historically underfunded areas and institutions across the country. Utilizing partnerships between the IDeA-CTR program and the CTSA network would help bring the essential training of the next generation of clinical and translational researchers to rural and underfunded areas.
- At least \$90 million in appropriated funding for the [Cures Acceleration Network](#) (CAN), an increase of at least \$15 million over FY 2026.
- Please provide the Centers for Disease Control and Prevention (CDC) with at least \$11.6 billion, an estimated increase of \$2.4 billion over FY 2026, and invest in various chronic disease activities.
- Please provide the Agency for Healthcare Research and Quality (AHRQ) with at least \$500 million, an estimated increase of \$154.6 million over FY 2026, and continue to preserve the integrity of this distinct and impactful agency.